Search Results

You are looking at 1 - 10 of 54 items for :

  • "schizophrenia" x
  • Medical and Health Sciences x
  • All content x
Clear All

Möller, H-J.: From Kraepelin to DSM-V: The concept of schizophrenia. Nemzetközi Szkizofrénia Szimpózium kivonata. Budapest, 2006. Murray, R. M., Dutta, R.: The right answer for the wrong reasons

Open access

Tandon, R., Nasrallah, H. A., Keshavan, M. S.: Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr. Res., 2010, 122 , 1

Restricted access
Orvosi Hetilap
Authors: Gabriella Inczédy-Farkas, Judit Benkovits, Nóra Balogh, Péter Álmos, Beáta Scholtz, Gábor Zahuczky, Zsolt Török, Krisztián Nagy, János Réthelyi, Zoltán Makkos, Ákos Kassai-Farkas, Anikó Égerházy, Judit Tűzkő, Zoltán Janka, István Bitter, György Németh, László Nagy, and Mária Judit Molnár

Seshadri, S., Kamiya, A., Yokota, Y. és mtsai: Disrupted-in-Schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade. Proc. Natl. Acad. Sci. USA, 2010, 107 , 5622

Open access

Van Os, J., Kapur, S.: Schizophrenia. Lancet, 2009, 374 , 635–645. Kapur S. Schizophrenia Lancet 2009

Open access
Orvosi Hetilap
Authors: László Fodor, István Fehér, György Szabados, Éva Júlia Varga, Róbert Herold, and Tamás Tényi

BH, Kim JH, Oh S, et al. Clinical features of parricide in patients with schizophrenia. Aust N Z J Psychology 2012; 46: 621–629. 12 Klein CA, Hirachan S. The masks of

Open access

4394 Rubin, L. H., Carter, C. S., Drogos, L., et al.: Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res., 2010, 124 , 13

Open access

Conley, R. R., Kelly, D. L.: Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr. J. Psychiatry Relat. Sci., 2005, 42 , 51

Restricted access
Orvosi Hetilap
Authors: Róbert Pilisi, Tamás Tényi, András Büki, Norbert Kovács, Antal Zemplényi, Gabriella Sebestyén, Péter Osváth, Sándor Fekete, and Viktor Vörös

cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulat. 2012; 5: 337–346. 33 Rostami R, Kazemi R, Nitsche MA

Open access

therapeutic agents for schizophrenia. Recent Patents CNS Drug Discover. 1, 43–53 (2006) Hashimoto K. Glycine transporter inhibitors as therapeutic agents for schizophrenia

Restricted access

seizures, stroke, and schizophrenia also lacks proof. The arguments on an immune-mediated illness are not strong enough either. A more likely cause could be an infectious disease, such as malaria, meningitis, or encephalitis, which might be exaggerated by

Open access